Fig. 5: Regression models predicting GOS–E Peds scores using plasma proteomic profiles at 72 h for discharge and 24 h for 3-month outcomes in pediatric severe traumatic brain injury patients. | Pediatric Research

Fig. 5: Regression models predicting GOS–E Peds scores using plasma proteomic profiles at 72 h for discharge and 24 h for 3-month outcomes in pediatric severe traumatic brain injury patients.

From: Aptamer-based proteomics in pediatric patients with severe traumatic brain injury: a pilot study

Fig. 5

a 72 h for discharge; b 24 h for 3-month outcome. CCL4L1 C-C motif chemokine ligand 4-like 1, CXCL9 C-X-C motif chemokine ligand 9, DSC2 desmocollin-2, GHR growth hormone receptor, GOSE Glasgow outcome scale – extended, pediatric revision, KLK3 kallikrein-related peptidase 3, KRAS Kirsten rat sarcoma viral oncogene homolog, NCR1 natural cytotoxicity triggering receptor 1, NRXN3 neurexin-3, PIANP PILR alpha-associated neural protein, Rsq square of the Pearson correlation coefficient, SPOCK1 testican-1, USP25 ubiquitin-specific peptidase 25.

Back to article page